Highlights BioXcel Therapeutics, Inc.

Equities

BTAI

US09075P1057

Market Closed - Nasdaq Other stock markets 01:30:00 26/06/2024 am IST			5-day change	1st Jan Change
1.18 ^USD	-0.84%		-3.28%	-60.00%

25/06	Bioxcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating Prn Treatment of Igalmi? (Dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia	CI
09/05	BioXcel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bioxcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating Prn Treatment of Igalmi? (Dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia	25/06	CI
BioXcel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
BioXcel Therapeutics to Launch At-Home Trial of Potential Bipolar, Schizophrenia Agitation Treatment	22/04	MT
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential	22/04	CI
Bioxcel Therapeutics, Inc. Announces Transquility In-Care Pivotal Phase 3 Trial Plan with Bxcl501 for Agitation Associated with Alzheimer's Dementia	10/04	CI
BioXcel Therapeutics Prices $25 Million Registered Direct Offering of Shares, Warrants	25/03	MT
BioXcel Therapeutics Gets European Patent for Method of Treating Agitation in Dementia	15/03	MT
BioXcel Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	12/03	CI
North American Morning Briefing : Inflation Data -2-	12/03	DJ
North American Morning Briefing : Nvidia Ignites -2-	22/02	DJ
BioXcel Therapeutics' BXCL701 Granted FDA Fast-Track Designation to Treat Small Cell Neuroendocrine Prostrate Cancer	13/02	MT
BioXcel Therapeutics Shares Rise Premarket on FDA Fast-Track Designation	12/02	DJ
BioXcel Therapeutics, Inc. Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer	12/02	CI
Positive Quarterly Earnings Boost Exchange-Traded Funds, Equity Futures Pre-Bell Friday	09/02	MT
BioXcel Therapeutics, Inc. Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of Bxcl701 in Combination with Keytruda®	06/02	CI
BioXcel Therapeutics, Inc. Announces USPTO's Allowance of Patent Application for Method of Treating Agitation in Alzheimer's Disease Using Oromucosal Formulations of Dexmedetomidine	05/02	CI
BioXcel Therapeutics Aligning With FDA Recommendation on Phase 3 Trial, Agrees to Amended Financing Terms	14/11	MT
BioXcel Therapeutics Shares Sink After Weak 3Q	14/11	DJ
BioXcel Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
BioXcel Therapeutics, Inc. Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer of Adenocarcinoma Phenotype	08/11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BioXcel Therapeutics, Inc.

Equities

BTAI

US09075P1057

Highlights

Filters